Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statistical practice in high-throughput screening data analysis.

Nathalie Malo1, James A Hanley, Sonia Cerquozzi

  • 1McGill University and Genome Quebec Innovation Centre, 740 avenue du Docteur Penfield, Montreal, Quebec, Canada, H3A 1A4.

Nature Biotechnology
|February 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Lancet regional health. Americas·2026
Same author

Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban <i>versus</i> aspirin in JAK2-Positive myeloproliferative neoplasms.

Haematologica·2026
Same author

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

The Journal of allergy and clinical immunology·2026
Same author

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis.

The World Allergy Organization journal·2026
Same author

A cellular basis for the mammalian nocturnal-diurnal switch.

Science (New York, N.Y.)·2026
Same author

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Journal of the American Academy of Dermatology·2026

High-throughput screening (HTS) requires robust statistical methods for accurate hit identification. Incorporating replicate measurements improves data analysis, enhancing the reliability of drug discovery hits.

Area of Science:

  • Drug discovery
  • Biotechnology
  • Computational chemistry

Background:

  • High-throughput screening (HTS) is crucial for identifying drug candidates from large compound libraries.
  • Current statistical tools for HTS hit detection lack confidence and robustness.
  • Challenges include positional effects, hit threshold selection, and minimizing error rates.

Purpose of the Study:

  • To examine statistical methods for data preprocessing and hit identification in primary HTS.
  • To address concerns regarding well positional effects and hit threshold determination.
  • To emphasize the need for replicate measurements to improve HTS accuracy.

Main Methods:

  • Statistical analysis of HTS data.
  • Evaluation of methods for data preprocessing and hit identification.

Related Experiment Videos

  • Investigation of replicate measurement strategies.

    • Main Results:

    • Current statistical approaches in HTS may not adequately address data variability.
    • Replicate measurements are essential for validating HTS data analysis assumptions.
    • Robust statistical methods combined with replicates enhance hit detection reliability.

    Conclusions:

    • Integrating replicate measurements with robust statistical methods is vital for primary HTS.
    • This integration improves the accuracy of hit identification, reducing false positives and negatives.
    • Enhanced HTS statistical analysis leads to more reliable drug discovery outcomes.